Protein Engineering of the Antitumor Enzyme PpADI for Improved Thermal Resistance. Issue 2 (20th December 2013)
- Record Type:
- Journal Article
- Title:
- Protein Engineering of the Antitumor Enzyme PpADI for Improved Thermal Resistance. Issue 2 (20th December 2013)
- Main Title:
- Protein Engineering of the Antitumor Enzyme PpADI for Improved Thermal Resistance
- Authors:
- Zhu, Leilei
Cheng, Feng
Piatkowski, Victoria
Schwaneberg, Ulrich - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Arginine deiminase (ADI, EC 3.5.3.6) is a potential antitumor drug for the treatment of arginine‐auxotrophic tumors such as hepatocellular carcinomas (HCCs) and melanomas. Studies in human lymphatic leukemia cell lines have confirmed the anti‐angiogenic activity of ADI. Activity and thermal resistance limit the efficacy of ADI in treatment of auxotrophic tumors. Previously, we reengineered ADI from <italic>Pseudomonas plecoglossicida</italic> (PpADI) for improved activity under physiological conditions (37 °C, PBS buffer, pH 7.4) by two rounds of directed evolution and combination of beneficial substitutions through site‐directed mutagenesis. The best variant, PpADI M6 (K5T/D38H/D44E/A128T/E296K/H404R), showed a 64.7‐fold improvement in <italic>k</italic><sub>cat</sub> value and a 37.6 % decreased <italic>S</italic><sub>0.5</sub> value under physiological conditions. However, M6 lost rapidly its activity (half‐life of ∼2 days at 37 °C). Here we report the re‐engineering of PpADI M6 for improved thermal resistance by directed evolution in order to increase its half‐life under physiological conditions. Directed evolution and recombination of the two most beneficial positions yielded variant PpADI M9 (K5T/D38H/D44E/A128T/V140L/E296K/F325L/H404R), for which the <italic>T</italic><sub>m</sub> value increased from 47 (M6) to 54 °C (M9); this corresponds to an increased half‐life from ∼2 days (M6) to ∼3.5 days<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Arginine deiminase (ADI, EC 3.5.3.6) is a potential antitumor drug for the treatment of arginine‐auxotrophic tumors such as hepatocellular carcinomas (HCCs) and melanomas. Studies in human lymphatic leukemia cell lines have confirmed the anti‐angiogenic activity of ADI. Activity and thermal resistance limit the efficacy of ADI in treatment of auxotrophic tumors. Previously, we reengineered ADI from <italic>Pseudomonas plecoglossicida</italic> (PpADI) for improved activity under physiological conditions (37 °C, PBS buffer, pH 7.4) by two rounds of directed evolution and combination of beneficial substitutions through site‐directed mutagenesis. The best variant, PpADI M6 (K5T/D38H/D44E/A128T/E296K/H404R), showed a 64.7‐fold improvement in <italic>k</italic><sub>cat</sub> value and a 37.6 % decreased <italic>S</italic><sub>0.5</sub> value under physiological conditions. However, M6 lost rapidly its activity (half‐life of ∼2 days at 37 °C). Here we report the re‐engineering of PpADI M6 for improved thermal resistance by directed evolution in order to increase its half‐life under physiological conditions. Directed evolution and recombination of the two most beneficial positions yielded variant PpADI M9 (K5T/D38H/D44E/A128T/V140L/E296K/F325L/H404R), for which the <italic>T</italic><sub>m</sub> value increased from 47 (M6) to 54 °C (M9); this corresponds to an increased half‐life from ∼2 days (M6) to ∼3.5 days (M9) under physiological conditions. Structure analysis of the homology model of M9 showed that the beneficial substitutions V140L and F325L likely promote the formation of tetrameric PpADI, which has greater thermal resistance than dimeric PpADI.</p> </abstract> … (more)
- Is Part Of:
- Chembiochem. Volume 15:Issue 2(2014)
- Journal:
- Chembiochem
- Issue:
- Volume 15:Issue 2(2014)
- Issue Display:
- Volume 15, Issue 2 (2014)
- Year:
- 2014
- Volume:
- 15
- Issue:
- 2
- Issue Sort Value:
- 2014-0015-0002-0000
- Page Start:
- 276
- Page End:
- 283
- Publication Date:
- 2013-12-20
- Subjects:
- Biochemistry -- Periodicals
Molecular biology -- Periodicals
Pharmaceutical chemistry -- Periodicals
572 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1439-7633 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cbic.201300433 ↗
- Languages:
- English
- ISSNs:
- 1439-4227
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3133.490980
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3076.xml